M. Cho, E. Moscicki, W. Narrow, D. Rae, B. Locke et al., Concordance between two measures of depression in the Hispanic Health and Nutrition Examination Survey, Social Psychiatry and Psychiatric Epidemiology, vol.3, issue.4, pp.156-63, 1993.
DOI : 10.1007/BF00797317

. American-psychiatric-association, Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) United States, 2013.

J. Lieberman, T. Stroup, J. Mcevoy, M. Swartz, R. Rosenheck et al., Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1232, 2005.
DOI : 10.1056/NEJMoa051688

J. Haro, D. Novick, J. Bertsch, J. Karagianis, M. Dossenbach et al., Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study, The British Journal of Psychiatry, vol.199, issue.3, pp.194-201, 2011.
DOI : 10.1192/bjp.bp.110.082065

P. Khanna, T. Suo, K. Komossa, H. Ma, C. Rummel-kluge et al., Aripiprazole versus other atypical antipsychotics for schizophrenia Autophagy has a key role in the pathophysiology of schizophrenia, Cochrane Database Syst Rev Mol Psychiatry, vol.1, 2013.

Y. Cao and D. Klionsky, Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein, Cell Research, vol.12, issue.10, pp.839-888, 2007.
DOI : 10.1016/j.cell.2006.12.044

N. Mizushima, Autophagy: process and function, Genes & Development, vol.21, issue.22, pp.2861-73, 2007.
DOI : 10.1101/gad.1599207

URL : http://www.genesdev.org/cgi/content/short/21/22/2861

S. Mandel, G. Rechavi, I. Gozes, S. Mandel, A. Torchinsky et al., Activity-dependent neuroprotective protein (ADNP) differentially interacts with chromatin to regulate genes essential for embryogenesis Activity-dependent neuroprotective protein: a novel gene essential for brain formation Cloning and characterization of the human activity-dependent neuroprotective protein Silencing of the ADNP-family member, ADNP2, results in changes in cellular viability under oxidative stress, I. Novel Evolutionary-conserved Role for the Activity-dependent Neuroprotective Protein (ADNP) Family That Is Important for Erythropoiesis, pp.814-2483, 2001.

T. Nakamachi, M. Li, S. Shioda, A. Arimura, E. Dresner et al., Signaling involved in pituitary adenylate cyclase-activating polypeptide-stimulated ADNP expression Activity-dependent neuroprotective protein (ADNP) expression level is correlated with the expression of the sister protein ADNP2: deregulation in schizophrenia, Peptides Eur Neuropsychopharmacol, vol.27, issue.16, pp.1859-64355, 2006.

S. Ripke, O. Dushlaine, C. Chambert, K. Moran, J. Kahler et al., Genome-wide association analysis identifies 13 new risk loci for schizophrenia, Nature Genetics, vol.72, issue.10, pp.1150-9578, 2013.
DOI : 10.1176/appi.ajp.2012.11091423

S. Mandel, I. Spivak-pohis, and I. Gozes, ADNP Differential Nucleus/Cytoplasm Localization in Neurons Suggests Multiple Roles in Neuronal Differentiation and Maintenance, Journal of Molecular Neuroscience, vol.123, issue.2, pp.127-168, 2008.
DOI : 10.1007/s12031-007-9013-y

I. Divinski, L. Mittelman, and I. Gozes, A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication, Journal of Biological Chemistry, vol.279, issue.27, pp.28531-28539, 2004.
DOI : 10.1074/jbc.M403197200

I. Gozes, D. Ishultzman, I. Pinhasov, A. Mandel, S. Grigoriadis et al., The femtomolar-acting NAP interacts with microtubules: Novel aspects of astrocyte protection Oz S, Ivashko-Pachima Y, Gozes I. The ADNP Derived Peptide, NAP Modulates the Tubulin Pool: Implication for Neurotrophic and Neuroprotective Activities Activity-dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model, J Alzheimers Dis PLoS One J Pharmacol Exp Ther, vol.6, issue.323, pp.37-41438, 2004.

N. Shiryaev, R. Pikman, E. Giladi, and I. Gozes, Protection Against Tauopathy by the Drug Candidates NAP (Davunetide) and D-SAL: Biochemical, Cellular and Behavioral Aspects, Current Pharmaceutical Design, vol.17, issue.25, pp.2603-2615, 2011.
DOI : 10.2174/138161211797416093

M. Chagny, V. Fournet, A. Schweitzer, C. Chevarin, J. Deloulme et al., The deletion of STOP/MAP6 protein in mice triggers highly altered mood and impaired cognitive performances The stop null mice model for schizophrenia displays [corrected] cognitive and social deficits partly alleviated by neuroleptics, Schizophr Bull J Neurochem Neuroscience Neuropharmacology, vol.39, issue.52, pp.969-7899, 2007.

K. Powell, S. Hori, R. Leslie, A. Andrieux, H. Schellinck et al., Cognitive impairments in the STOP null mouse model of schizophrenia STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood status of STOP/MAP6 KO mice The suppression of brain cold-stable microtubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders, Behav Neurosci Behav Brain Res J Neurochem Genes Dev Mol Pain, vol.121, issue.6, pp.826-35257, 2002.

F. Messanvi, B. Giros, and M. Hamon, The deletion of the microtubule-associated STOP protein affects the serotonergic mouse brain network Microtubule-associated STOP protein deletion triggers restricted changes in dopaminergic neurotransmission, J Neurochem Bouvrais-Veret C J Neurochem, vol.115, issue.104, pp.1579-94745, 2008.

E. Brenner, U. Sonnewald, A. Schweitzer, A. Andrieux, and A. Nehlig, Hypoglutamatergic activity in the STOP knockout mouse: A potential model for chronic untreated schizophrenia, Journal of Neuroscience Research, vol.18, issue.15, pp.3487-93, 2007.
DOI : 10.1002/jnr.21200

URL : https://hal.archives-ouvertes.fr/inserm-00379976

P. Brun, M. Begou, A. Andrieux, L. Mouly-badina, M. Clerget et al., Dopaminergic transmission in STOP null mice Both chronic treatments by epothilone D and fluoxetine increase the short-term memory and differentially alter the mood-status of STOP/MAP6 KO mice The stop null mice model for schizophrenia displays cognitive and social deficits partly alleviated by neuroleptics STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating, J Neurochem J Neurochem Neuroscience Behav Brain Res, vol.94, issue.163, pp.63-7329, 2005.

A. Andrieux, P. Salin, A. Schweitzer, M. Begou, B. Pachoud et al., Microtubule stabilizer ameliorates synaptic function and behavior in a mouse model for schizophrenia NAP (davunetide) enhances cognitive behavior in the STOP heterozygous mouse--a microtubule-deficient model of schizophrenia, Neuroprotective effects of NAP against excitotoxic brain damage in the newborn mice, pp.1224-301368, 2006.

J. Lieberman, D. Goff, J. Csernansky, and J. Mcevoy, Effect of the neuroprotective peptide davunetide (AL-108) on cognition and functional capacity in schizophrenia, Schizophr Res, vol.136, pp.25-31, 2012.

L. Jarskog, Z. Dong, A. Kangarlu, T. Colibazzi, R. Girgis et al., Effects of Davunetide on N-acetylaspartate and Choline in Dorsolateral Prefrontal Cortex in Patients with Schizophrenia, Neuropsychopharmacology, vol.157, issue.7, pp.1245-52, 2013.
DOI : 10.1038/npp.2013.23

R. Alcalay, E. Giladi, C. Pick, and I. Gozes, Intranasal administration of NAP, a neuroprotective peptide, decreases anxiety-like behavior in aging mice in the elevated plus maze, Neuroscience Letters, vol.361, issue.1-3, pp.128-159, 2004.
DOI : 10.1016/j.neulet.2003.12.005

D. Selch, T. Kraus, R. Dittmann, T. Pollmacher, and A. Schuld, Sleep propensity at daytime as assessed by Multiple Sleep Latency Tests (MSLT) in patients with schizophrenia increases with clozapine and olanzapine, Schizophr Res, vol.135, pp.123-130, 2012.

H. Moore, M. Geyer, C. Carter, and D. Barch, Harnessing cognitive neuroscience to develop new treatments for improving cognition in schizophrenia: CNTRICS selected cognitive paradigms for animal models, Neuroscience & Biobehavioral Reviews, vol.37, issue.9, pp.2087-91, 2013.
DOI : 10.1016/j.neubiorev.2013.09.011

P. Heiser, F. Enning, J. Krieg, H. Vedder, A. Feldman et al., Idan Tau and caspase 3 as targets for neuroprotection Haloperidol and clozapine block formation of autophagolysosomes in rat primary neurons Esteves AR, Gozes I, Cardoso SM. The rescue of microtubule-dependent traffic recovers mitochondrial function in Parkinson's disease Loss of STOP protein impairs peripheral olfactory neurogenesis Scents and nonsense: olfactory dysfunction in schizophrenia, J Psychopharmacol Int J Alzheimers Dis Neuroscience Biochim Biophys Acta PLoS One Turetsky BI Schizophr Bull, vol.21, issue.35, pp.851-6493670, 2007.

E. Giladi, J. Romano, and I. Gozes, NAP, a femtomolar-acting peptide, protects the brain against ischemic injury by reducing apoptotic death 56. Zemlyak I, Sapolsky R, Gozes I. NAP protects against cytochrome c release: inhibition of the initiation of apoptosis, Stroke Eur J Pharmacol, vol.33, issue.618, pp.1085-929, 2002.

S. Oz, O. Kapitansky, Y. Ivashco-pachima, A. Malishkevich, E. Giladi et al., The NAP motif of activity-dependent neuroprotective protein (ADNP) regulates dendritic spines through microtubule end binding proteins Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze, Mol Psychiatry J Pharmacol Exp Ther, vol.293, issue.60, pp.1091-1099, 2000.

M. Cochav, K. Vered, P. Newton, and P. Aisen, NAP: research and development of a peptide derived from activity-dependent neuroprotective protein (ADNP), CNS Drug Rev, vol.11, pp.353-68, 2005.

B. Morimoto, I. De-lannoy, A. Fox, I. Gozes, and A. Stewart, Davunetide: Pharmacokinetics and distribution to brain after intravenous or intranasal administration to rat, chimica Oggi / CHEMISTRY today, vol.27, pp.16-20, 2009.

C. Hiemke, A. Dragicevic, G. Grunder, S. Hatter, J. Sachse et al., Therapeutic Monitoring of New Antipsychotic Drugs, Therapeutic Drug Monitoring, vol.26, issue.2, pp.156-60, 2004.
DOI : 10.1097/00007691-200404000-00012